TriNutra’s ThymoQuin black seed oil gains European patent for composition

Black seed oil supplier TriNutra (Harrison, NY) announced a new European Patent for its ThymoQuin cold-pressed black seed oil (Nigella sativa). The company says ThymoQuin’s unique makeup offers improved stability and bioavailability of its key active ingredient, thymoquinone. It says ThymoQuin is the first cold-pressed black seed oil to be standardized to 3% thymoquinone.

“Thymoquinone, a key and potent active component in Nigella sativa (black seed oil), is unstable in the presence of oxidants like free fatty acids,” the firm’s press release states. “This leads to reduced potency of the black seed oil and rancidity. It was, therefore, a major goal of TriNutra to find a way to standardize and stabilize its black seed oil.”

The company says ThymoQuin may provide benefits for obese individuals suffering certain metabolic conditions. The new patent cites how ThymoQuin’s composition was able to increase expression of the OPA1, MFN1, and MFN2 proteins in obese mice.

“These results suggest our standardized, cold-pressed, full-spectrum black seed oil is both stable and highly bioavailable,” stated TriNutra’s CEO, Morris Zelkha, in the press release. “Such composition was shown to improve the impaired mitochondrial functions related to metabolism and energetic processes in the mitochondria and therefore has the potential to assist in managing metabolic conditions using low dosage and high efficacy.” Animal studies have also shown ThymoQuin decreasing blood glucose, LDL, and oxidized LDL while increasing VO₂ and balancing blood pressure, the company adds.